Global Licensing Expansion Santhera’s licensing agreements across North America, China, and India demonstrate a strong interest in expanding the reach of its flagship product AGAMREE. This presents sales opportunities for regional distribution partners and local healthcare providers seeking innovative treatments for Duchenne muscular dystrophy.

Recent Funding & Growth The recent USD 13 million royalty monetization financing indicates increased financial stability and growth potential, enabling Santhera to invest in marketing, distribution, and expanding sales efforts within its markets and beyond.

Product Launch Opportunities With the launch of DMD therapy in the UK following NICE approval and strategic partnerships to fill distribution gaps, there are potential opportunities to introduce similar innovative neuromuscular treatments in other European and Asian markets.

Market Focus & Potential Santhera’s focus on rare neuromuscular diseases targets a high unmet medical need, suggesting a niche but lucrative market. Connecting with specialized clinics, hospitals, and patient advocacy groups could enhance sales channels for AGAMREE and future products.

Regulatory & Commercial Strategy Santhera’s regulatory approvals from major agencies like the FDA, EMA, and MHRA, along with distribution partnerships, indicate a solid path for entering and expanding in key markets. This creates opportunities for customized sales strategies targeting healthcare providers and payers.